Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone prolongs survival without disease worsening…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
A Phase 1 clinical trial is recruiting patients with hard-to treat or relapsed multiple myeloma to evaluate Mustang Bio’s investigational autologous (patient-derived)…
Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated…
The National Institute for Health and Care Excellence (NICE) in England has recommended treatment with Revlimid (lenalidomide) and dexamethasone for multiple myeloma…
Cellectar Biosciences’ candidate CLR 131 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma…
The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (…
